ICER Enhanced Patient Engagement Program Will Be Led By Former Biopharma Exec
Executive Summary
Yvette Venable has more than 20 years’ experience in patient advocacy, heath policy and biopharma communications.
You may also be interested in...
Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Novo Nordisk’s Cardiovascular Claim For Wegovy Will Enable Medicare Coverage, CBO Assumes
Medicare has not issued a policy allowing for Part D coverage of obesity drugs with additional health claims like Wegovy’s. But expectations are growing that it will.
Lilly Pre-Approval Spadework Includes Alzheimer’s Blood Test Development, Unbranded DTC Ads
Donanemab’s review delay will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research. The company has also been supporting development of blood-based tools for early diagnoses, though they would not eliminate PET scans.